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With over 5000journalsindexed inPubMed, theannouncement
of a new journal generally elicits a raised brow along with some
variation on these questions: Do weneed another journal? Who
can read even 10% of the journals covering neuropsychiatric
science, either basic or clinical? Will more journals just permit
more publishing of mediocre science? The answers depend on
the journal or, more speciﬁcally, on the topic.
TranslationalPsychiatryaddressesatopicthatistimelyand
important. The parallel revolutions in basic neuroscience
and genetics have not translated to a revolution in clinical
psychiatry. Indeed, few clinical researchers and even fewer
cliniciansunderstandthetransformativepowerofthechanges
that have taken place in the past decade in both genetics
and neuroscience. The reason is simple: genetics and
neuroscience have not yet proven actionable for clinical
psychiatry. All of the discoveries of rare and common variants
associated with mental illnesses should prove useful as
portals into the pathophysiology of schizophrenia or bipolar
disorder, and they may reveal ‘druggable’ targets. However in
2011, none of these ﬁndings are changing how clinicians
diagnose or treat serious mental illness. Although neuro-
imaging has given us a window into brain development,
connectivity and function, is there any scan that reliably
inﬂuences clinical care? Even the early diagnosis of Alzhei-
mer’s disease, one broadly recognized application of positron
emission tomography imaging, has yet to be shown to change
the course of dementia.
Would it be irrational exuberance to claim that this ‘valley of
death’ between basic science and clinical care is about to be
bridged? I think the bridge is already well underway, and the
spanis not only from the traditional‘bench to bedside’ but also
increasingly from the clinic to the lab and back again. Indeed,
if there is a culture shift that underscores the timeliness
of Translational Psychiatry, it is the blurring of what used to be
thedividebetweenbasicandclinicalresearch.Considerafew
examples,allofwhicharetakenfromcurrentNationalInstitute
of Mental Health-funded projects:
 Discovery of a new risk gene in people with schizophrenia
or autism leads to studies of this variant in neural
development in a mouse or synaptic plasticity in slices,
searchingforcellularpathwaysthatmightexplainabnormal
brain function.
 Induced pluripotent stem cells from people with 16p11.2 or
22q11.2 mutations are differentiated into parvalbumin-
positive interneurons along with pyramidal cells to create
a ‘disease in a dish’ that can be used for high-throughput
screening of small-molecule modiﬁers.
 Splice variants of candidate genes are mapped in the
developing human cortex to identify where and when
sequence variation alters transcription.
Are these basic or clinical studies? For most of the twenty-
ﬁrstcentury,sciencemaynotbedividedintothesecategories.
What we call ‘translational’ today will likely become the center
of our efforts: humans will be the animal model of choice, and
information from human studies will guide bench science as
often as bench discoveries inﬂuence human research.
Of course, the real test of translation will be its impact
onpublic healthmorethan its impact onscience. That bridgeis
still very much under construction, but it is perhaps the best
argument for Translational Psychiatry. Public health impact,
measuredasa decreaseinmorbidityand mortality,willdepend
on three breakthroughs in our understanding of mental illness.
First, we need biomarkers for early detection. Currently, all
mental illnesses are diagnosed by abnormal behavior and
cognition. We know from other brain disorders (for example,
Parkinson’s, Huntington’s and Alzheimer’s disease) that
changes in behavior and cognition are a late stage of a chronic
process, and we know from other areas of medicine (for
example, cardiovascular disease and cancer) that early
detection and early interventions are associated with better
outcomes. Neuroimaging, genomics and perhapsother ‘omics’
will give us these biomarkers for mental disorders. Second, we
need pre-emptive interventions for those detected to be at risk
or those in pre-symptomatic stages of a mental illness. These
interventions could include medication, but more likely will be
psychosocial supports for families or devices such as video
games to improve executive function. Finally, we need better
treatments for people with symptoms. Current medications
are not good enough. Translational science can yield new
molecular targets, new small molecules and a generation of
new early-phase clinical trials that focus on speciﬁc domains
of function rather than diagnostic categories. Again, we have
experience with this drug discovery process for other medical
disorders.Withtheadventofnovelmoleculartargetsformental
disorders, we can expect a generation of new small molecules,
some of which will become entirely new classes of treatments,
perhaps as adjuncts to psychosocial treatments as part of a
personalized approach to care.
These three breakthroughs will be necessary, but not
sufﬁcient,forbendingthecurveofmorbidityandmortalityfrom
mental illness. A lesson learned from the rest of medicine is
relevant to Translational Psychiatry. There are three spans to
the translational bridge: the traditional span (T1), described in
the previous paragraph, bridges bench and bedside, or
perhaps more often in psychiatry, from imaging lab to imaging
suite. Equally important will be the bridge from clinical lab to
practice (T2). The gap between clinical science and clinical
practice is legendary in medicine, where a decade or more
can separate a new discovery from its broad implementation
in practice. The gap in psychiatry is even greater, as most
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hence much of mental health care is provided in schools,
homes and institutions outside traditional health care.
Translational research that focuses on implementation and
dissemination needs breakthroughs as much as T1 research.
However, there is yet another span, especially important
for psychiatry. The T3 span is the bridge from practice
to policy. Even if a $20000 positron emission tomography
scan could reliably diagnose bipolar disorder (T1), and
even if this could be shown to work in a ‘real world’ clinic
(T2), would this scan be reimbursed by payors or required
by guidelines (T3)? If translational science only makes
mental health care more expensive and less accessible,
we cannot expect to be successful in terms of public
health impact.
Alloftheseissuesarewithinthedomainofthisnew,exciting
journal Translational Psychiatry. Yes, there are too many
journals for anyone to read, and yes, this proliferation will lead
to too many papers being published. However, Translational
Psychiatry has an opportunity to make a difference by
publishing the best science at a time when we can see this
historic bridge being built that will link science, practice and
policy. I, for one, will watch (and read) with enthusiasm.
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